GOTHENBURG, Sweden, April 13, 2011 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery and cell based assay research, is entering a new expansion phase. The decided share issue will strengthen Cellectricon's capital base and enable a focused market expansion and value-growth of the product portfolio. The company's recently launched high throughput systems, Cellaxess(R)HT and Dynaflow(R)HT have been developed in close collaboration with leading global pharmaceutical companies and esteemed research facilities to meet the industry's increasing demand for fully automated, highly efficient systems for drug discovery applications.
To view the Multimedia News Release, please click:
Axel Broms, Chairman of Cellectricon, says:
"2010 was a progressive year for Cellectricon with the signing of several high-profile collaboration agreement including leading pharmaceutical companies and world-renowned research facilities. I am very pleased to note the validation of Cellectricon by an investor such as Dunross & Co."
Cellectricon AB, Sweden, is a leading life sciences solutions provider of advanced screening products to accelerate drug discovery and cell-based assay research. The company's proprietary products & services solve critical bottlenecks in the drug discovery & cell based research including the industry leading platforms for high resolution ion-channel screening, and cell engineering. Developed in close collaboration with leaders in the pharmaceutical industry and esteemed research labs, the Cellaxess(R)HT System enables high throughput transfection for genomic screening and the new Dynaflow(R)HT System greatly advances ion channel drug discovery.